WAVEMAN · COMPANY

ASND · Ascendis Pharma A/S

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV+4.49% 13F +693CRM+2.92% 13F +1,018CVNA-0.98% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+4.91% 13F +1,203CRWD+5.68% 13F +1,382ANET+1.22% 13F +1,323COIN+10.14% 13F +475

← ALL COMPANIES

ASND

Name: Ascendis Pharma A/S (ASND) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

Ascendis Pharma A/S

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001612042

C-SUITE BUYING · 1FORM 144 · 1☆ WATCH

INSIDER NET · 180D

-$3.9M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

190

13F, latest reported quarter

REVENUE GROWTH

XBRL, annual

NET MARGIN

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$3.9M over 180 days

+$430.3K over 90 days

below 76% of Pharma & Biotech

CONGRESS

no member of Congress has reported trading it

FUNDS

190 funds added or opened last quarter

more than 86% of Pharma & Biotech

REVENUE

no revenue reported in any filing

MARGIN

no margin: this company reports no revenue to divide by

BUYBACKS

no share repurchases reported

SHORT

5.5% of shares outstanding short · 7.2 days to cover · settled 2026-07-31

more than 57% of Pharma & Biotech

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

190 funds added or opened positions in the latest 13F quarter, of 313 holders.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +35.9%

+35.9%12M

INSIDER BUYINSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $3.9M sold by insiders over 180 days, 190 funds added last quarter, $62.3K in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, Ascendis Pharma A/S insiders sold a net $3.9M of stock across 11 Form 4 purchases and sales, with 2 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-05.

INSIDER

FILED

VALUE

HOLTUG LARS

Director

SELL

2026-09-02

236.0

$62.3K

BIENAIME JEAN JACQUES

Director

BUY

2026-08-14

1,100.0

$270.4K

BIENAIME JEAN JACQUES

Director

BUY

2026-08-14

900.0

$222.2K

SMITH SCOTT THOMAS

EVP & Chief Financial Officer

BUY

2026-06-02

100.0

$21.9K

BIENAIME JEAN JACQUES

Director

BUY

2026-05-29

200.0

$44.8K

11 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 6 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

RA CAPITAL MANAGEMENT, L.P.

10,281,496.0 sh

$2.7B

Avoro Capital Advisors LLC

5,111,111.0 sh

$1.4B

WESTFIELD CAPITAL MANAGEMENT CO LP

4,798,267.0 sh

$1.3B

Jupiter Topco LLC

3,648,772.0 sh

$973.4M

FMR LLC

3,545,575.0 sh

$945.7M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

HOLTUG LARS

FILED 2026-09-02

$62.3K

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Spyglass Growth Fund

$49.5M POSITION · AS OF 2026-03-31

5.9%

Artisan Small Cap Fund

$52.2M POSITION · AS OF 2026-03-31

5.9%

Artisan Mid Cap Fund

$155.2M POSITION · AS OF 2026-03-31

5.2%

Artisan Global Discovery Fund

$5.7M POSITION · AS OF 2026-03-31

5.2%

CTIVP - Westfield Select Large Cap Growth Fund

$81.2M POSITION · AS OF 2026-03-31

5.2%

Touchstone Strategic Trust-Touchstone Mid Cap Growth Fund

$76.5M POSITION · AS OF 2026-03-31

4.2%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 13 registered trials, 6 still enrolling or running — a status change here is dated weeks before the press release

Phase 2

2 ACTIVE

Phase 3

2 ACTIVE

Not applicable

2 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
GROSS PROFIT	$625.2M	$319.4M	$222.3M	$39.0M
NET INCOME	$-228.0M	$-378.1M	$-481.4M	$-583.2M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-05 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE